¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26
±³À°ÀÏÀÚ : 2021-08-26
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : À±ÁöÇö
¿¬¶ôó : 070-4895-6129  
À̸ÞÀÏ : bmt@kams.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-26 CH A 09:30~10:00 NGS-based MRD Monitoring Pre- and Post-Allogeneic HSCT for AML  Michael Heuser(MHH Hospital) 
±³À°½Ã°£ 08-26 CH A 10:00~10:30 Conditioning Intensity of Allogeneic Transplantation for AML with MRD  Christopher S. Hourigan(NIH) 
±³À°½Ã°£ 08-26 CH A 10:40~11:10 Engineering and Design for Next Generation CAR-T Cells  Sham Mailankody(MSKCC) 
±³À°½Ã°£ 08-26 CH A 11:20~11:50 Machine Learning Research for Hematopoietic Stem Cell Transplantation  Yasuyuki Arai(Kyoto University) 
±³À°½Ã°£ 08-26 CH A 11:50~12:20 Current Statistical Issues in Hematopoietic Cell Transplantation  Haesook T. Kim(Dana-Farber Cancer Institute) 
±³À°½Ã°£ 08-26 CH B 12:40~13:20 Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation  Thomas Martin(University of California San Francisco) 
±³À°½Ã°£ 08-26 CH A 13:30~14:30 Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants  Eun Sang Yi(Korea University Guro Hospital) 
±³À°½Ã°£ 08-26 CH A 14:40~15:10 High Throughput Single Cell Analysis in AML  Koichi Takahashi(MDACC) 
±³À°½Ã°£ 08-26 CH A 15:10~15:40 Therapeutic Implications in AML using Prospective Genomic Profiling  Omar Abdel-Wahab(MSKCC) 
±³À°½Ã°£ 08-26 CH A 15:40~16:10 Clonal Hematopiesis of Indeterminate Potential in Transplantation  Kyoung Ha Kim(Soonchunhyang University Hospital) 
±³À°½Ã°£ 08-26 CH A 16:30~17:00 FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML  Richard T. Maziarz(Oregon Health and Science University) 
±³À°½Ã°£ 08-26 CH A 17:00~17:30 Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS  Tapan Kadia(MDACC) 
±³À°½Ã°£ 08-26 CH A 17:30~18:00 Treatment Strategies after Allogeneic HSCT in Relapsed ALL  Ik-Chan Song(Chungnam National University College of Medicine) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 26ÀÏ (1ÀÏÂ÷) : 2021-08-26""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2021 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ (ICBMT 2021 Virtual) - 8¿ù 27ÀÏ (2ÀÏÂ÷) : 2021-08-27
´ÙÀ½±Û (¿Â¶óÀÎ) Á¦19ȸ ±è¾È°úº´¿ø ½ÉÆ÷Áö¾ö : 2021-08-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
435 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ The 17th Postgraduate Course of Diabetes : 2018-09-15 0 845 2018-08-15
434 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-15 0 879 2018-08-15
433 Á¦ÁÖ ´ëÇÑÄ¡·áÃÊÀ½ÆÄÇÐȸ Á¦4ȸ Á¤±âÇмú´ëȸ : 2018-09-14 0 963 2018-08-15
432 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 3ÀÏÂ÷ : 2018-09-14 0 2,514 2018-08-15
431 °æ³² ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ¿µ³²ÁöºÎ 2018³â 9¿ù Áý´ãȸ : 2018-09-14 0 970 2018-08-15
430 °æ±â ±¹¸³¾Ï¼¾ÅÍ 2018³â 3Â÷ ÀÇ»ý¸í°úÇÐÆ÷·³ : 2018-09-14 0 771 2018-08-15
429 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-14 0 632 2018-08-15
428 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-14 0 1,483 2018-08-15
427 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 2ÀÏÂ÷ : 2018-09-13 0 1,551 2018-08-15
426 ¼­¿ï ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø À̺ñÀÎÈÄ°ú Áý´ãȸ : 2018-09-11 0 511 2018-08-15
425 °æ±â ÇѾç´ëÇб³±¸¸®º´¿ø °©»ó¼± Á¾¾çÀÇ Áø´Ü°ú Ä¡·á: Ãֽŵ¿Çâ : 2018-09-11 0 453 2018-08-15
424 ºÎ»ê Á¦493Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2018-09-10 0 514 2018-08-15
423 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 12ȸ °¡Å縯¼ºÇü½ÉÆ÷Áö¾ö : 2018-09-09 0 801 2018-08-15
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 797 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 811 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷